BRAF and metastatic melanoma: The discovery that ∼50% of tumors are driven by BRAFV600 mutations has led to the development of targeted therapies (TT) based on selective inhibitor of mutant BRAF (vemurafenib, dabrafenib or encorafenib), used clinically in combination with a MEK inhibitor (cobimetinib, trametinib or binimetinib) for the treatment of advanced metastatic melanoma [22–24].